Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 4
Submit an article Journal homepage
308
Views
9
CrossRef citations to date
0
Altmetric
Letters to the Editor

Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors

Federica SoràDepartment of Hematology, Catholic University of Sacred Heart, Rome, Italy;
,
Francesca Romana PonzianiDepartment of Internal Medicine and Gastroenterology, Catholic University of Sacred Heart, Rome, Italy
,
Luca LaurentiDepartment of Hematology, Catholic University of Sacred Heart, Rome, Italy;
,
Patrizia ChiusoloDepartment of Hematology, Catholic University of Sacred Heart, Rome, Italy;
,
Francesco AutoreDepartment of Hematology, Catholic University of Sacred Heart, Rome, Italy;
,
Antonio GasbarriniDepartment of Internal Medicine and Gastroenterology, Catholic University of Sacred Heart, Rome, Italy
,
Simona SicaDepartment of Hematology, Catholic University of Sacred Heart, Rome, Italy;
&
Maurizio PompiliDepartment of Internal Medicine and Gastroenterology, Catholic University of Sacred Heart, Rome, ItalyCorrespondence[email protected]
 show all
Pages 993-995 | Received 07 Jun 2016, Accepted 25 Jul 2016, Published online: 22 Aug 2016

References

  • EASL (European Association for the Study of the Liver) clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.
  • Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–220.
  • Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39:397–408.
  • Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–611.
  • Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699–712.
  • Bréchot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”? Hepatology. 2001;34:194–203.
  • Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221–244.
  • Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215–219.
  • Lai GM, Yan SL, Chang CS, et al. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol. 2013;19:1318–1321.
  • Ikeda K, Shiga Y, Takahashi A, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma. 2006;47:155–157.
  • Kang BW, Lee SJ, Moon JH, et al. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol. 2009;90:383–387.
  • Kim SG, Chun JM, Jin R, et al. Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. Transplant Proc. 2010;42:843–845.
  • Ando T, Kojima K, Isoda H, et al. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. Int J Hematol. 2015;102:379–380.
  • Koo YX, Tay M, Teh YE, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011;90:1219–1223.
  • Pompili M, Basso M, Hohaus S, et al. Prospective study of hepatitis B virus reactivation in patients with hematological malignancies. Ann Hepatol. 2015;14:168–174.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.